Honduras
Tuberculosis profile
| High HIV burden |
Population  2012 7.9 million
Estimates of TB burden * 2012 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.23 (<0.01–0.85) 2.9 (0.08–11)
Mortality (HIV+TB only) 0.041 (0.023–0.063) 0.51 (0.29–0.8)
Prevalence  (includes HIV+TB) 6.5 (2.1–13) 82 (27–168)
Incidence  (includes HIV+TB) 4.3 (2.8–6.1) 54 (35–77)
Incidence (HIV+TB only) 0.17 (0.1–0.25) 2.1 (1.3–3.2)
Case detection, all forms (%) 70 (49–110)    
TB case notifications 2012        
New cases   (%) Retreatment cases (%)
Smear-positive 1 945 (69) Relapse 198 (86)
Smear-negative 509 (18) Treatment after failure    
Smear-unknown / not done 0 (0) Treatment after default    
Extrapulmonary 362 (13) Other 32 (14)
Other 0 (0)      
Total new 2 816   Total retreatment 230  
           
Other (history unknown) 0        
Total new and relapse 3 014   Total cases notified 3 046  
New cases Smear-positive Smear-negative/ unknown/
not done
Extrapulmonary
M:F ratio 1.6 1.6 1.2
Age < 15 33 90 41
Laboratories 2012
Smear (per 100 000 population) 2.1
Culture (per 5 million population) 3.2
Drug susceptibility testing (per 5 million population) 0.6
Is second-line drug susceptibility testing available? Yes, outside
country
Treatment success rate 2011 (%)        
New smear-positive and/or culture-positive 88   Is rifampicin used
throughout treatment for
new patients?
Yes
New smear-negative/extrapulmonary    
Retreatment 68  
TB/HIV 2012 Number (%)
TB patients with known HIV status 2 312 (76)
HIV-positive TB patients 259 (11)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 135 (52)
HIV-positive TB patients on antiretroviral therapy (ART) 192 (74)
HIV-positive people screened for TB    
HIV-positive people provided with IPT 286  
Estimates of MDR-TB burden 2012*   New   Retreatment
% of TB cases with MDR-TB 1.8 (0.76–3.4) 12 (5.8–22)
MDR-TB cases among notified pulmonary
TB cases
43 (19–84) 28 (13–51)
Reported cases of MDR-TB 2012 New Retreatment Total
Cases tested for MDR-TB 41 (2%) 96 (42%) 161
Laboratory-confirmed MDR-TB cases 0 6 6
Patients started on MDR-TB treatment     6
Financing TB control 2013
National TB programme budget (US$ millions) 5.9
% Funded domestically 3%
% Funded internationally 47%
% Unfunded 50%
***
(Rate per 100 000 population per year)
Mortality graph
___ Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
___ Prevalence

(Rate per 100 000 population per year)
Incidence graph
__ Notifications Incidence
___
___ Incidence (HIV+TB only)

Treatment success rate (%)
tx success graph
__ New smear-positive and/or culture-positive
__ New smear-negative/extrapulmonary __
Retreatment

(Number of patients)
CPT ART graph
__ HIV-positive TB patients
__ on CPT __ on ART

Total budget (US$ millions)
Budget funding Graph
__ Funded domestically __ Funded internationally
__ Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 * Ranges represent uncertainty intervals Generated: 2014-04-23 Data: www.who.int/tb/data